These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30924421)

  • 1. Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis.
    Muhammad A; Madhav D; Rawish F; Viveksandeep TC; Albert E; Mollie J; Prateek S
    Curr Clin Pharmacol; 2019; 14(3):166-174. PubMed ID: 30924421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
    Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
    J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.
    Daley P; Louie T; Lutz JE; Khanna S; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
    J Antimicrob Chemother; 2017 Dec; 72(12):3462-3470. PubMed ID: 28961905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
    Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
    Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
    Cannon K; Byrne B; Happe J; Wu K; Ward L; Chesnel L; Louie T
    J Antimicrob Chemother; 2017 Dec; 72(12):3453-3461. PubMed ID: 28927227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and development of surotomycin for the treatment of Clostridium difficile.
    Knight-Connoni V; Mascio C; Chesnel L; Silverman J
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):195-204. PubMed ID: 26670919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With
    Boix V; Fedorak RN; Mullane KM; Pesant Y; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
    Open Forum Infect Dis; 2017; 4(1):ofw275. PubMed ID: 28480267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
    Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH
    J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.
    Kravets AM; Hanneke R; Nelson RL
    Tech Coloproctol; 2023 Dec; 28(1):20. PubMed ID: 38112980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro.
    Aldape MJ; Rice SN; Field KP; Bryant AE; Stevens DL
    J Med Microbiol; 2018 Dec; 67(12):1689-1697. PubMed ID: 30307842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.
    Adams HM; Li X; Mascio C; Chesnel L; Palmer KL
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4139-47. PubMed ID: 25941217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
    Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
    JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
    Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
    Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
    Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.
    Cheknis A; Devaris D; Chesnel L; Dale SE; Nary J; Sambol SP; Citron DM; Goering RV; Johnson S
    J Antimicrob Chemother; 2020 Nov; 75(11):3120-3125. PubMed ID: 32747931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
    Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
    Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
    Deshpande A; Hurless K; Cadnum JL; Chesnel L; Gao L; Chan L; Kundrapu S; Polinkovsky A; Donskey CJ
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3333-9. PubMed ID: 26976870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
    Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
    J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity.
    Di X; Bai N; Zhang X; Liu B; Ni W; Wang J; Wang K; Liang B; Liu Y; Wang R
    Braz J Infect Dis; 2015; 19(4):339-49. PubMed ID: 26001980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.